A. Letai, Diagnosing and exploiting cancer's addiction to blocks in apoptosis, Nature Reviews Cancer, vol.417, issue.2, pp.121-132, 2008.
DOI : 10.1038/nrc2297

M. Certo, D. G. Moore, V. Nishino, M. Wei, G. Korsmeyer et al., Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members, Cancer Cell, vol.9, issue.5, pp.351-365, 2006.
DOI : 10.1016/j.ccr.2006.03.027

M. Davids, A. Roberts, M. Anderson, J. Pagel, B. Kahl et al., The BCL-2- Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study, ASH Annu Meet Abstr, vol.120, p.304, 2012.

A. Souers, J. Leverson, E. Boghaert, S. Ackler, N. Catron et al., ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, Nature Medicine, vol.559, issue.2, 2013.
DOI : 10.1038/leu.2009.151

G. Foight, J. Ryan, S. Gullá, A. Letai, and A. Keating, Designed BH3 Peptides with High Affinity and Specificity for Targeting Mcl-1 in Cells, ACS Chemical Biology, vol.9, issue.9, 2014.
DOI : 10.1021/cb500340w

N. Munshi, T. Hideshima, D. Carrasco, M. Shammas, D. Auclair et al., Identification of genes modulated in multiple myeloma using genetically identical twin samples, Blood, vol.103, issue.5, pp.1799-1806, 2004.
DOI : 10.1182/blood-2003-02-0402

S. Wuillème-toumi, N. Robillard, P. Gomez, P. Moreau, L. Gouill et al., Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival, Leukemia, vol.96, issue.7, pp.1248-1252, 2005.
DOI : 10.1093/jnci/djh122

A. Roberts, J. Seymour, J. Brown, W. Wierda, T. Kipps et al., Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease, Journal of Clinical Oncology, vol.30, issue.5, pp.488-496, 2012.
DOI : 10.1200/JCO.2011.34.7898

L. Bodet, P. Gomez-bougie, C. Touzeau, C. Dousset, G. Descamps et al., ABT-737 is highly effective against molecular subgroups of multiple myeloma, Blood, vol.118, issue.14, pp.3901-3910, 2011.
DOI : 10.1182/blood-2010-11-317438

C. Touzeau, C. Dousset, L. Gouill, S. Sampath, D. Leverson et al., The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma, Leukemia, vol.21, issue.1, 2013.
DOI : 10.1038/leu.2013.216

A. Morales, M. Kurtoglu, S. Matulis, J. Liu, D. Siefker et al., Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells, Blood, vol.118, issue.5, pp.1329-1339, 2011.
DOI : 10.1182/blood-2011-01-327197

R. Pan, L. Hogdal, J. Benito, D. Bucci, L. Han et al., Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia, Cancer Discovery, vol.4, issue.3, pp.362-375, 2014.
DOI : 10.1158/2159-8290.CD-13-0609

T. Chonghaile, J. Roderick, C. Glenfield, J. Ryan, S. Sallan et al., Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199, Cancer Discovery, vol.4, issue.9, pp.1074-1087, 2014.
DOI : 10.1158/2159-8290.CD-14-0353

J. Ryan and A. Letai, BH3 profiling in whole cells by fluorimeter or FACS. Methods San Diego Calif, pp.156-164, 2013.
DOI : 10.1016/j.ymeth.2013.04.006

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686919

S. Kumar, R. Vij, J. Kaufman, J. Mikhael, T. Facon et al., Phase I Interim Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM), Clinical Lymphoma Myeloma and Leukemia, vol.15, p.2015
DOI : 10.1016/j.clml.2015.07.630